The scientist’s investigation covers issues in Internal medicine, Cancer, Colorectal cancer, Surgery and Oncology. His research in Internal medicine intersects with topics in Gastroenterology and Pathology. The various areas that he examines in his Cancer study include Inflammation, Immunology, Quality of life, Disease and Physical therapy.
Stephen Clarke has researched Colorectal cancer in several fields, including Bevacizumab, Rectum and Fluorouracil. His studies in Surgery integrate themes in fields like Clinical trial and FOLFIRI. His Oncology study combines topics from a wide range of disciplines, such as Radiation therapy and FOLFOX.
His main research concerns Internal medicine, Oncology, Cancer, Colorectal cancer and Chemotherapy. His Internal medicine research includes elements of Gastroenterology, Surgery and Pathology. His biological study deals with issues like Retrospective cohort study, which deal with fields such as Univariate analysis.
Stephen Clarke interconnects Quality of life, Immunology, Alternative medicine, Disease and Physical therapy in the investigation of issues within Cancer. His Colorectal cancer research integrates issues from Bevacizumab and Fluorouracil. His research integrates issues of Stage, Regimen, Radiation therapy and Toxicity in his study of Chemotherapy.
Stephen Clarke mainly focuses on Internal medicine, Oncology, Immune system, Cancer research and Cancer. Stephen Clarke regularly ties together related areas like Gastroenterology in his Internal medicine studies. His Oncology study combines topics in areas such as Prospective cohort study, Pancreatic cancer and Chemotherapy.
The concepts of his Immune system study are interwoven with issues in Inflammation, Lymphatic system, Muscularis mucosae and Cytokine. His Cancer research research is multidisciplinary, relying on both Non small cell, Cell, Lung and Immunotherapy. His study looks at the relationship between Colorectal cancer and fields such as Metastasis, as well as how they intersect with chemical problems.
His primary areas of study are Internal medicine, Immune system, Cancer research, Cytotoxic T cell and Cell. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Oncology. The study incorporates disciplines such as Microbiome, Colitis and Microbiology in addition to Immune system.
His Cancer research study incorporates themes from Dendritic cell, CD8, Function, Cytotoxic drug and Antigen presentation. His Cytotoxic T cell research incorporates elements of Colorectal cancer, Flow cytometry, Chemotherapy and Mass cytometry. His work deals with themes such as Chemokine, Cytokine and Glioma, which intersect with Cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Leonard B. Saltz;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer.
Journal of Clinical Oncology (2008)
Cancer-related inflammation and treatment effectiveness
Connie I Diakos;Kellie A Charles;Donald C McMillan;Stephen J Clarke.
Lancet Oncology (2014)
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Graeme J.K. Guthrie;Kellie A. Charles;Campbell S.D. Roxburgh;Paul G. Horgan.
Critical Reviews in Oncology Hematology (2013)
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
Jim Cassidy;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer.
Journal of Clinical Oncology (2008)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero.
Lancet Oncology (2012)
Clinical Pharmacokinetics of Docetaxel
Stephen J. Clarke;Laurent P. Rivory.
Clinical Pharmacokinectics (1999)
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
W Chua;K A Charles;V E Baracos;S J Clarke;S J Clarke.
British Journal of Cancer (2011)
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
Nico van Zandwijk;Nick Pavlakis;Steven C Kao;Anthony Linton.
Lancet Oncology (2017)
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.
M J Proctor;D C McMillan;D S Morrison;C D Fletcher.
British Journal of Cancer (2012)
Regulation of Drug Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer
Edward T. Morgan;Kerry B. Goralski;Micheline Piquette-Miller;Kenneth W. Renton.
Drug Metabolism and Disposition (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: